Sources of European drug consumption data at a country level

International Journal of Public Health

Volumn 59, Issue 5, 2014, Pages 877-887

  Ferrer, Pili ^a   Ballarín, Elena ^a,b,c   Sabaté, Mònica ^a,b,c   Laporte, Joan Ramon ^a,b,c   Schoonen, Marieke ^d   Rottenkolber, Marietta ^e   Fortuny, Joan ^f   Hasford, Joerg ^e   Tatt, Iain ^g   Ibáñez, Luisa ^a,b,c  

^a Fundacion Institut Catala de Farmacologia   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d AMGEN LTD   (United Kingdom)

^e UNIVERSITY OF MUNICH   (Germany)

^f Novartis Pharma AG   (Spain)

^g Information and Ophthalmology   (Switzerland)

Author keywords

Databases; Drug consumption; Europe; Nationwide

Indexed keywords

DRUG INDUSTRY; DRUG UTILIZATION; EUROPE; FACTUAL DATABASE; HUMAN; INTERNET; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

DATABASES, FACTUAL; DRUG INDUSTRY; DRUG PRESCRIPTIONS; DRUG UTILIZATION; EUROPE; HUMANS; INTERNET; PHARMACOEPIDEMIOLOGY; QUESTIONNAIRES;

EID: 84919844964     PISSN: 16618556     EISSN: 1420911X     Source Type: Journal    
DOI: 10.1007/s00038-014-0564-8     Document Type: Article

References (40)

1. Adriaenssens N, Coenen S, Muller A, Vankerckhoven V, Goossens H, ESAC Project Group (2010) European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. J Antimicrob Chemother 65:769–774
2. Agence Nationale de Sécurité du Médicament et des Produits de Santé (2012). Médicaments. Rapports scientifiques et techniques. ANSM, France. http://www.ansm.sante.fr/Mediatheque/Publications/Rapports-Syntheses-Medicaments#med. Accessed 28 January 2014
3. Bernard M, Bénichou J, Blin P, Weill A, Bégaud B, Abouelfath A, Moore N, Fourrier-Réglat A, on behalf of the CADEUS team (2012) Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Pharmacoepidemiol Drug Saf 21:573–583
4. Bradley CP (1992) Factors which influence the decision whether or not to prescribe: the dilemma facing general practitioners. Br J Gen Practice 42:454–458
5. Brewer L, Kennett K, McGreevy D, Williams D (2013) A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol. doi:10.1007/s00228-013-1483-y
6. Buchnera F, Goepffarthb D, Wassem J (2013) The new risk adjustment formula in Germany: implementation and first experiences. Health Policy 109:253–262
7. Callréus T (2007) Use of desmopressin in elderly patients in Denmark. Pharmacoepidemiol Drug Saf 16:995–998
8. Capellà D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug utilization studies. Methods and uses, WHO Regional Publications European Series No. 45, Copenhagen, pp 55–78
9. Capellà D, Pedrós C, Vidal X, Laporte JR (2002) Case-Population Studies in Pharmacoepidemiology. Drug Saf 25:7–19
10. Center for Disease Control and Prevention (2011). Determining patient days for summary data collection: observation vs inpatients. http://www.cdc.gov/nhsn/PDFs/PatientDay_SumData_Guide.pdf. Accessed 28 January 2014
11. Cross-National Comparison of Drug Utilisation. European Drug Utilisation Group (EURODURG) (2008). Resources for cross national comparison of drug utilization data. In: Proceedings of the 24th international conference on pharmacoepidemiology and therapeutic risk management held in Copenhagen, Denmark. Pharmacoepidemiol Drug Saf 17(Supplement1):S117
12. Curtis C, Marriott J, Langley C (2004) Development of a prescribing indicator for objective quantification of antibiotic usage in secondary care. J Antimicrob Chemother 54:529–533
13. Donoghue JM, Tylee A (1996) The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiat 168:164–168
14. Ekedahl A, Månsson N (2004) Unclaimed prescriptions after automated prescription transmittals to pharmacies. Pharm World Sci 26:26–31
15. Filius PM, Liem TB, van der Linden PD, Janknegt R, Natsch S, Vulto AG, Verbrugh HA (2005) An additional measure for quantifying antibiotic use in hospitals. J Antimicrob Chemother 55:805–808
16. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106:86–94
17. Gagliotti C, Mazzetti I, Moro ML (2009) Comparison of sales and reimbursement data regarding outpatient antibiotic use in a northern Italian Region. Pharmacoepidemiol Drug Saf 18:1115–1118
18. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garouliene K, Herholz H, Joppi R, Kalaba M, Laius O, McGinn D, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay F, Vlahović-Palčevski F, Wendykowska K, Wettermark B, Zara C, Gustafsson LL (2010) Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 10:707–722
19. Himmel W, Kochen MM, Sorns U, Hummers-Pradier E (2004) Drug changes at the interface between primary and secondary care. Int J Clin Pharmacol 42:103–109
20. Johnell K, Fastbom J (2011) Antiepileptic drug use in community-dwelling and institutionalized elderly: a nationwide study of over 1 300 000 older people. Eur J Clin Pharmacol 67:1069–1075
21. Khong T, de Vries F, Goldenberg J, Klungel O, Robinson N, Ibáñez L, Petri H (2012) Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int 91:24–31
22. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish national prescription registry. Scand J Public Health 39(Suppl 7):38–41
23. Kurz X (2011) Measuring drug utilisation–importance in pharmacoepidemiology. In: Presentation of the International Society for Pharmacoepidemiology and EuroDURG, The European branch of the Special Interest Group for Drug Utilization Research (SIGDUR) held in Antwerp 2011 November 30–December 3, Antwerp, Belgium
24. L’Assurance Maladie (2012). Statistiques et Publications. AMELI, France. http://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/index.php. Accessed 28 January 2014
25. Lapi F, Tuccori M, Motola D, Pugi A, Vietri M, Montanaro N, Vaccheri A, Leoni O, Cocci A, Leone R, Conforti A, Moretti U, Sessa E, Mazzaglia G, Mugelli A, Mazzei T, Vannacci A (2010) Safety profile of fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy. Drug Saf 33:789–790
26. Larsen MD, Cars T, Hallas J (2013) A mini review of the use of hospital-based databases in observational inpatient studies of drugs. Basic Clin Pharmacol Toxicol 112:13–18
27. Lu Y, Hernandez P, Abegunde D, Edejer T (2011) Medicine expenditures. The world medicines situation 2011, 3rd edn. The World Health Organization, Geneva
28. Panneman MJM, Goettsch WG, Kramarz P, Herings RMC (2003) The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a pharmo study. Drugs Aging 20:833–839
29. Prieto-Alhambra D, Petri H, Goldenberg JS, Khong TP, Klungel OH, Robinson NJ, de Vries F (2014) Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA. Osteoporos Int. Published online first January 22 2014
30. Richardson K, Kenny RA, Peklar J, Bennett K (2013) Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicating health. J Clin Epidemiol 66:1308–1316
31. Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58:323–337
32. Sorensen HT, Sabroe S, Olsen J (1996) A framework for evaluation of secondary data sources for epidemiological research. Int J Epidemiol 25:435–442
33. Stolk P, Schneeweiss S, Leufkens HGM, Heerdink ER (2008) Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives. Contraception 78:399–404
34. Tobi H, van den Heuvel NN, de Jong-van den Berg, Lolkje TW (2004) Does uncollected medication reduce the validity of pharmacy dispensing data? Pharmacoepidemiol Drug Saf 13:497–500
35. van Walraven C, Austin P (2012) Administrative database research has unique characteristics that can risk biased results. J Clin Epidemiol 65:126–131
36. Vincat database. Methodology (2011) Canal Salut. Generalitat de Catalunya. http://www20.gencat.cat/portal/site/canalsalut/menuitem.3ed60a9c7692da35ba963bb4b0c0e1a0/?vgnextoid=dc4e5c473a3ad210VgnVCM2000009b0c1e0aRCRD&vgnextchannel=dc4e5c473a3ad210VgnVCM2000009b0c1e0aRCRD&vgnextfmt=detall&contentid=5b0c703a8600e210VgnVCM2000009b0c1e0aRCRD. Accessed 20 February 2014
37. Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N, Landauer R (2010) The PHIS Hospital Pharma Report. Pharmaceutical Health Information System Project. http://whocc.goeg.at/Publications/Articles. Accessed 20 February 2014
38. Walley T (2003) The EuroMedicines project. J Headache Pain 4(Suppl 1):S59–S62
39. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. http://www.whocc.no. Accessed 2014 January 24
40. Zaharan NL, Williams D, Bennett K (2013) Prescribing of antidiabetic therapies in Ireland: 10-year trends 2003–2012. Ir J Med Sci. doi:10.1007/s11845-013-1011-1